These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 30862160)
1. Monitoring the Immunoproteasome in Live Cells Using an Activity-Based Peptide-Peptoid Hybrid Probe. Zerfas BL; Trader DJ J Am Chem Soc; 2019 Apr; 141(13):5252-5260. PubMed ID: 30862160 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and Application of an Activity-Based Peptide-Peptoid Hybrid Probe for the Immunoproteasome. Zerfas BL; Trader DJ Curr Protoc Chem Biol; 2019 Dec; 11(4):e76. PubMed ID: 31860787 [TBL] [Abstract][Full Text] [Related]
3. Approaches to Evaluate the Impact of a Small-Molecule Binder to a Noncatalytic Site of the Proteasome. Tian W; Maresh ME; Trader DJ Chembiochem; 2021 Jun; 22(11):1961-1965. PubMed ID: 33617657 [TBL] [Abstract][Full Text] [Related]
4. Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time. Zerfas BL; Coleman RA; Salazar-Chaparro AF; Macatangay NJ; Trader DJ ACS Chem Biol; 2020 Sep; 15(9):2588-2596. PubMed ID: 32786259 [TBL] [Abstract][Full Text] [Related]
5. Selective Substrates and Activity-Based Probes for Imaging of the Human Constitutive 20S Proteasome in Cells and Blood Samples. Rut W; Poręba M; Kasperkiewicz P; Snipas SJ; Drąg M J Med Chem; 2018 Jun; 61(12):5222-5234. PubMed ID: 29806773 [TBL] [Abstract][Full Text] [Related]
7. Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes. Cornish Carmony K; Sharma LK; Lee DM; Park JE; Lee W; Kim KB Chembiochem; 2015 Jan; 16(2):284-92. PubMed ID: 25477005 [TBL] [Abstract][Full Text] [Related]
8. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Bandoh N; Ogino T; Cho HS; Hur SY; Shen J; Wang X; Kato S; Miyokawa N; Harabuchi Y; Ferrone S Tissue Antigens; 2005 Sep; 66(3):185-94. PubMed ID: 16101829 [TBL] [Abstract][Full Text] [Related]
9. A bright approach to the immunoproteasome: development of LMP2/β1i-specific imaging probes. Carmony KC; Lee DM; Wu Y; Lee NR; Wehenkel M; Lee J; Lei B; Zhan CG; Kim KB Bioorg Med Chem; 2012 Jan; 20(2):607-13. PubMed ID: 21741845 [TBL] [Abstract][Full Text] [Related]
10. Purification and separation of the 20S immunoproteasome from the constitutive proteasome and identification of the subunits by LC-MS. Dechavanne V; Vilbois F; Glez L; Antonsson B Protein Expr Purif; 2013 Feb; 87(2):100-10. PubMed ID: 23147206 [TBL] [Abstract][Full Text] [Related]
11. Nonpeptidic Selective Inhibitors of the Chymotrypsin-Like (β5 i) Subunit of the Immunoproteasome. Sosič I; Gobec M; Brus B; Knez D; Živec M; Konc J; Lešnik S; Ogrizek M; Obreza A; Žigon D; Janežič D; Mlinarič-Raščan I; Gobec S Angew Chem Int Ed Engl; 2016 May; 55(19):5745-8. PubMed ID: 27037901 [TBL] [Abstract][Full Text] [Related]
12. Tunable Probes with Direct Fluorescence Signals for the Constitutive and Immunoproteasome. Dubiella C; Cui H; Groll M Angew Chem Int Ed Engl; 2016 Oct; 55(42):13330-13334. PubMed ID: 27709817 [TBL] [Abstract][Full Text] [Related]
13. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826 [TBL] [Abstract][Full Text] [Related]
14. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. de Bruin G; Xin BT; Kraus M; van der Stelt M; van der Marel GA; Kisselev AF; Driessen C; Florea BI; Overkleeft HS Angew Chem Int Ed Engl; 2016 Mar; 55(13):4199-203. PubMed ID: 26511210 [TBL] [Abstract][Full Text] [Related]
15. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Xi J; Zhuang R; Kong L; He R; Zhu H; Zhang J Eur J Med Chem; 2019 Nov; 182():111646. PubMed ID: 31521028 [TBL] [Abstract][Full Text] [Related]
16. Immunoproteasome functions explained by divergence in cleavage specificity and regulation. Winter MB; La Greca F; Arastu-Kapur S; Caiazza F; Cimermancic P; Buchholz TJ; Anderl JL; Ravalin M; Bohn MF; Sali A; O'Donoghue AJ; Craik CS Elife; 2017 Nov; 6():. PubMed ID: 29182146 [TBL] [Abstract][Full Text] [Related]
17. The Immunoproteasome: An Emerging Target in Cancer and Autoimmune and Neurological Disorders. Zerfas BL; Maresh ME; Trader DJ J Med Chem; 2020 Mar; 63(5):1841-1858. PubMed ID: 31670954 [TBL] [Abstract][Full Text] [Related]
18. Structural Elucidation of a Nonpeptidic Inhibitor Specific for the Human Immunoproteasome. Cui H; Baur R; Le Chapelain C; Dubiella C; Heinemeyer W; Huber EM; Groll M Chembiochem; 2017 Mar; 18(6):523-526. PubMed ID: 28098422 [TBL] [Abstract][Full Text] [Related]
19. Emerging role of immunoproteasomes in pathophysiology. Kaur G; Batra S Immunol Cell Biol; 2016 Oct; 94(9):812-820. PubMed ID: 27192937 [TBL] [Abstract][Full Text] [Related]
20. Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells. Matharage JM; Minna JD; Brekken RA; Udugamasooriya DG ACS Chem Biol; 2015 Dec; 10(12):2891-9. PubMed ID: 26509598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]